Large Rise in French health Spending

23 July 1995

Spending by the French health funds in 1995 is growing fast, reports the major CNAM fund, rising 0.7% in May against 0.4% in March and 0.5% in April, and bringing growth in the last 12 months to 4%. The CNAM says revisions to medical and related fees largely explain May's growth, when spending reached 36 billion French francs ($7.4 billion) and brought total spending in the first five months of 1995 to 174.8 billion francs.

The CNAM adds that this growth is due to a "very strong advance" in reimbursement of medical fees and drug prescriptions, up 1.3% against 0.4% in April. Spending on drug reimbursement rose 1.7% in May against 1.1% in April.

Two-Tier Service Meantime, the economic research organization InSEE says that in 1991, people on the lowest income consulted doctors 20% less than the total population, compared to 15% less in 1980. In 1994 16.4% of people received health insurance through the social security system alone, of whom 3.3% were exempt from drug and treatment charges, compared with 30.5% in 1980 and 45.1% in 1960. In 1991, 82.8% of people were doubly covered by social security and private health insurance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight